Seagen Inc (SGEN)
212.50
+0.76
(+0.36%)
USD |
NASDAQ |
Oct 03, 16:00
212.87
+0.37
(+0.17%)
Pre-Market: 08:41
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 39.89B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 54.32% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 18.31 |
| Price to Book Value | 15.23 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 48.66% |
Profile
| Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies. |
| URL | https://www.seagen.com |
| Investor Relations URL | https://investor.seagen.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Oct. 27, 2023 (est.) |
| Last Earnings Release | Aug. 02, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies. |
| URL | https://www.seagen.com |
| Investor Relations URL | https://investor.seagen.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Oct. 27, 2023 (est.) |
| Last Earnings Release | Aug. 02, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |